Balboa Nephrology

The kidney is a modest organ. It does not announce itself the way a heart does. It filters roughly forty gallons of blood a day, adjusts your blood pressure, balances your minerals, and asks for nothing in return - until, quietly, it stops. By the time most people notice, the choices left are narrow and expensive: dialysis, transplant, or decline. This is the strange economics that Balboa Nephrology has spent five decades organizing itself around, and it turns out that building a business on a disease nobody sees coming requires a very particular kind of company.

Balboa started in San Diego in 1973 with two physicians. That is worth sitting with, because most things founded in 1973 are no longer here. The group is now, by its own account and by most external ones, the largest nephrology practice in California - somewhere north of sixty board-certified nephrologists plus advanced-care practitioners, spread across nineteen clinical offices and eighty-eight dialysis clinics from San Diego up through Orange County and out to the Imperial Valley. It manages more than 28,000 kidney patients and another 6,000-plus who are on dialysis or living with a transplant. As headcounts go, that is a mid-sized company caring for a small city.

What makes the group interesting is not the size - plenty of medical practices are large - but the shape. Balboa did not just add doctors. It vertically integrated a chronic disease. If you develop chronic kidney disease inside the Balboa system, the same organization can try to slow it down, put in your dialysis access, run your dialysis, manage your anemia, walk you through a transplant, follow you for the years afterward, and, if you're willing, enroll you in a clinical trial testing the drug that might have prevented the whole thing. Owning the entire pipeline of a single disease is an unusual strategy in American medicine, where fragmentation is closer to the default.

That research arm deserves its own paragraph, because it is the part that amuses. Balboa Research - formerly, and more grandly, the California Institute of Renal Research - runs clinical trials for pharmaceutical and device companies in CKD, end-stage renal disease, transplantation, and dialysis vascular access. Patients who join get access to state-of-the-art therapies, and - this is the fun part - they are frequently paid to participate. A fifty-year-old medical group that still runs a working trials lab is telling you something about its self-image: it would rather help invent the next treatment than wait for someone else to.

Then there is the money question, which in kidney care is enormous. End-stage renal disease is one of the most expensive conditions in the U.S. healthcare system, and for years the incentives were exactly backwards - the system paid more when patients got sicker. Balboa was an early and top-performing participant in the federal government's value-based experiments (the CMMI CEC and ESCO programs), the ones that flip the math so that keeping patients healthier and out of the hospital is what pays. In 2021 it became the first joint-venture partner of Evergreen Nephrology, a company launched by Adam Boehler's Rubicon Founders specifically to give nephrology groups the capital and technology to take on that risk. Evergreen has since raised well over a hundred million dollars and spread across two dozen states. Balboa was the proof of concept.

None of this changes what the work actually is on a Tuesday morning: a nephrologist reading labs, a nurse tending a fistula, a patient in a dialysis chair for the fourth hour. The infrastructure - the research lab, the value-based contracts, the vascular access center, the transplant institute - exists to make that Tuesday go better and, ideally, to make fewer of them necessary. That is the whole thesis. It is not glamorous. It has, however, lasted fifty years, which in this industry counts as a small miracle.

A rough sketch of Balboa's footprint across Southern California. Figures are drawn from the company's own reporting and are approximate.

Kidney disease has long punished the American healthcare system's incentives: the sicker a patient got, the more the system spent. Balboa built a reputation topping the federal government's early attempts to reverse that math - the CMMI CEC and ESCO programs, where the goal is fewer hospitalizations, not more.

In August 2021, that track record made it the natural first partner for Evergreen Nephrology, a new company from Adam Boehler's Rubicon Founders. Evergreen supplies capital, technology and the appetite for financial risk; the nephrologists supply the medicine. The pitch, in Evergreen's own framing, is blunt: saving lives and saving money can be the same project. Balboa was the first group to test whether that pitch held up in practice.